Skip to Content

Deferoxamine Injection

Last Updated: September 16, 2018
Status: Current

Products Affected - Description
    • Desferal injection, Novartis, 500 mg, vial, 4 count, NDC 00078-0467-91
    • Deferoxamine injection, Pfizer, 2 gram, vial, 4 count, NDC 00409-2337-25
    • Deferoxamine injection, Pfizer, 500 mg, vial, 4 count, NDC 00409-2336-10
Reason for the Shortage
    • Fresenius Kabi has deferoxamine on shortage due to increased demand.
    • Pfizer has deferoxamine on shortage due to manufacturing delays.
    • Novartis has Desferal on shortage due to increased demand.
    • Alvogen launched deferoxamine injection in mid-2018.
    • Apo-Pharma launched deferoxamine injection in mid-2018.
Available Products
    • Deferoxamine injection, Alvogen, 2 gram, vial, 1 count, NDC 47781-0624-07
    • Deferoxamine injection, Alvogen, 500 mg, vial, 1 count, NDC 47781-0623-07
    • Deferoxamine injection, Apo-Pharma, 2 gram, vial, 4 count, NDC 52609-4504-06
    • Deferoxamine injection, Apo-Pharma, 500 mg, vial, 4 count, NDC 52609-4505-06
    • Deferoxamine injection, Fresenius Kabi, 2 gram, vial, 1 count, NDC 63323-0599-30
    • Deferoxamine injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0597-10

Estimated Resupply Dates

    • Pfizer has deferoxamine 500 mg and 2 gram vials on back order and the company estimates a release date of September 2018 for the 500 mg vials and November 2018 for the 2 gram vials.
    • Novartis has Desferal 500 mg vials on allocation.

Updated

Updated September 16, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 7, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide